AMPH Stock: Amphastar Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live amph stock price $25.61, comprehensive Amphastar Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time amph stock data and investment insights.
Loading chart...
Company Overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Company Information
- CEO
- Yongfeng Zhang
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2028
Contact Information
- Website
- https://www.amphastar.com
- Address
- 11570 6th Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 11.3)
Business Model & Strategy
Amphastar Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Yongfeng Zhang, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Amphastar Pharmaceuticals, Inc. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 1.2 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Amphastar Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Amphastar Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Amphastar Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Amphastar Pharmaceuticals, Inc.
- ⚠Investors should consider how Amphastar Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.18B
P/E Ratio
11.33
Beta
0.91
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.18B market capitalization
- Trading Volume: 388.20K shares traded today
- Price Range: 52-week range of $20.39 - $41.13
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 1.18B, the company represents a significant player in its market. The stock is currently trading at $25.61 with a negativedaily change of 2.66%.
The company's 2028 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 11.33, beta of 0.91, and 52-week price range from $20.39 to $41.13when evaluating investment opportunities.
Why Invest in Amphastar Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Yongfeng Zhang
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.